Tissue Bank

组织库核心C将提供必要的机制来收集和分发来自 将患者数量发送给个别调查人员。由于Ph阴性的MPD相对罕见，个体 单一机构的研究人员无法从足够多的患者身上获得组织，无法到达 在没有组织核心C的合理时间范围内得出统计上有效的结论组织核心C将 提供来自这些疾病不同阶段的大量患者的组织，以及来自 个别患者在疾病发展过程中纵向收集。因此，组织库核心C将是 对于当前和未来关于MPD的研究来说，这是一个无价的工具。 组织库核心C的具体目标是： 1)接收、处理和存储来自MPD联盟临床站点诊断的MPD患者的组织 以高效和有组织的方式。2)为可关联的MPD组织提供中央存储库 基本数据将由生物统计和数据管理核心B存储。这些数据将包括临床 实验室数据和家庭人口学，将使选择和分配最适合的组织 每个翻译研究项目。3)使MPD容易获得可见的冷冻组织 研究研究的财团调查员。当组织可用时，科学工作者也可以使用组织 整个社区。4)进行生物标志物分析，旨在预测疾病进展和血栓形成 在诊断时收到的MPD样本，以及在治疗期间定期收到的MPD样本。 组织库核心C的功能是：1)获取Ph阴性的MPD组织；2)作为信息库 对于Ph阴性的MPD组织，3)进行MPD组织研究，4)进行生物标志物分析。 收集到的组织将提供给MPD联盟的成员和科学界，网址为 大号的。组织库核心C将极大地促进翻译研究，从而提高诊断和 MPD的分期，并最终导致分子靶向治疗的发展。 PV和IM是目前还没有有效治疗方法的疾病。PV和IM主要影响 50岁的患者及其年发病率估计为2.8/10万人和0.4/10万人， 分别进行了分析。50岁以上的人的数量正在增加，因此将有更多的人 在未来受到这些疾病的影响。因此，从公共卫生的角度来看，必须 开发有效的治疗方法。

The Tissue Bank Core C will provide the necessary mechanism to collect and distribute tissues from large numbers of patients to individual investigators. Because Ph negative MPD are relatively rare, individua investigators at a single institution cannot obtain tissues from sufficiently large numbers of patients to reach statistically valid conclusions within a reasonable time frame without Tissue Core C. Tissue Core C will provide tissues from large cohorts of patients at various stages of these disorders, as well as tissues from individual patients collected longitudinally during disease progression. Thus, the Tissue Bank Core C will be an invaluable tool to current and future studies on MPD. The specific aims of the Tissue Bank Core C are to: 1) Receive, process, and store tissues from MPD patients diagnosed at MPD Consortium clinical sites in an efficient and organized way. 2) Provide a central repository for MPD tissues that can be associated with basic data to be stored by Biostatistics and Data Management Core B. These data will include clinical laboratory data and familial demographics that will enable selection and distribution of tissues best suited for each translational research project. 3) Make the viably frozen tissues readily available to the MPD Consortium investigators for research studies. When available, tissues will also be available to the scientific community at large. 4) Perform biomarker assays, designed to predict disease progression and thrombotic complications, on MPD samples received at the time of diagnosis, and periodically during therapy. The functions of Tissue Bank Core C will be to: 1) acquire Ph negative MPD tissues, 2) act as a repository for the Ph negative MPD tissues, 3) distribute the MPD tissues research, and 4) perform biomarker analyses. Tissues collected will be available to members of the MPD Consortium and to the scientific community at large. Tissue Bank Core C will significantly facilitate translational research that will enhance diagnosis and staging of MPD and ultimately lead to the development of molecularly targeted therapies. PV and IM are disorders for which there are currently no effective treatments. PV and IM affect primarily patients > 50 years of age and their annual incidences are estimated to be 2.8 and 0.4/100,000 people, respectively. The number of people over the age of 50 is increasing and therefore more people will be affected by these disorders in the future. Therefore, from a public health perspective it is imperative to develop effective therapies.